Items where Author is "Ahmad, M"

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 18.

Journal article

Saif, JMS, Vadakekolathu, J, Rane, SS, McDonald, D, Ahmad, M ORCID: 0000-0002-6074-2001, Mathieu, M, Pockley, AG ORCID: 0000-0001-9593-6431, Durrant, L, Metheringham, R, Rees, RC and McArdle, SEB ORCID: 0000-0001-6929-9782, 2014. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. European Journal of Immunology, 44 (4), pp. 994-1004. ISSN 0014-2980

Mathieu, MG, Miles, AK, Ahmad, M, Buczek, ME, Pockley, AG, Rees, RC and Regad, T ORCID: 0000-0003-4028-6368, 2014. The helicase HAGE prevents interferon-a-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1. Cell Death and Disease, 5 (2). ISSN 2041-4889

Mathieu, MG, Miles, AK ORCID: 0000-0002-5388-938X, Ahmad, M, Buczek, ME, Pockley, AG ORCID: 0000-0001-9593-6431, Rees, RC and Regad, T ORCID: 0000-0003-4028-6368, 2014. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1. Cell Death & Disease, 5 (2). ISSN 2041-4889

Vafadar-Isfahani, B, Laversin, SA, Ahmad, M ORCID: 0000-0002-6074-2001, Ball, G, Coveney, C, Lemetre, C, Miles, AK ORCID: 0000-0002-5388-938X, Van Schalkwyk, G, Rees, RC and Matharoo-Ball, B, 2010. Serum biomarkers which correlate with failure to respond to immunotherapy and tumor progression in a murine colorectal cancer model. Proteomics Clinical Applications, 4 (89), pp. 682-696. ISSN 1862-8346

Zhang, W, Caspell, R, Karulin, AY, Ahmad, M ORCID: 0000-0002-6074-2001, Haicheur, N, Abdelsalam, A, Johannesen, K, Vignard, V, Dudzik, P, Georgakopoulou, K, Mihaylova, A, Silina, K, Aptsiauri, N, Adams, V, Lehmann, PV and McArdle, S ORCID: 0000-0001-6929-9782, 2009. ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring -- even in hands of ELISPOT-inexperienced investigators. Journal of Immunotoxicology, 6 (4), pp. 227-234. ISSN 1547-691X

Assudani, DP, Ahmad, M ORCID: 0000-0002-6074-2001, Li, G, Rees, RC and Ali, SA, 2006. Immunotherapeutic potential of DISC-HSV and OX40L in cancer. Cancer Immunology Immunotherapy, 55 (1), pp. 104-111. ISSN 0340-7004

Assudani, DP, Ahmad, M ORCID: 0000-0002-6074-2001, Li, G, Rees, RC and Ali, SA, 2006. Immunotherapeutic potential of DISC-HSV and OX40L in cancer. Cancer Immunology Immunotherapy, 55 (1), pp. 104-111. ISSN 0340-7004

Miles, AK ORCID: 0000-0002-5388-938X, Matharoo-Ball, B, Li, G, Ahmad, M ORCID: 0000-0002-6074-2001 and Rees, RC, 2006. The identification of human tumour antigens: current status and future developments. Cancer Immunology Immunotherapy, 55 (8), pp. 996-1003. ISSN 0340-7004

Boateng, J, Lancashire, L, Brown, P, Ahmad, M, Matharoo-Ball, B, Davy, R, Yang, SY, Roberts, J, Teale, P, Velloso, C, Rees, R, Ball, G ORCID: 0000-0001-5828-7129, Goldspink, G and Creaser, C, 2006. The use of proteomic and bioinformatics techniques for the detection of protein biomarkers following growth hormone administration. The Internet Journal of Genomics and Proteomics, 2 (2). ISSN 1540-2630

Li, G, Ali, SA, McArdle, SE ORCID: 0000-0001-6929-9782, Mian, S, Ahmad, M ORCID: 0000-0002-6074-2001, Miles, A ORCID: 0000-0002-5388-938X and Rees, RC, 2005. Immunity to tumour antigens. Current Pharmaceutical Design, 11 (27), pp. 3501-3509. ISSN 1381-6128

Assudani, DP, Ahmad, M ORCID: 0000-0002-6074-2001, Li, G, Rees, RC and Ali, SA, 2005. Immunotherapeutical potential of DISC-HSV and OX40L in cancer. Cancer Immunology Immunotherapy, pp. 1-8.

Ahmad, M ORCID: 0000-0002-6074-2001, Rees, RC, McArdle, SE ORCID: 0000-0001-6929-9782, Li, G, Mian, S, Entwisle, C, Loudon, P and Ali, SA, 2005. Regulation of CTL responses to MHC-restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4(+) T cells in mice failing immunotherapy with DISC-mGM-CSF. International Journal of Cancer, 115 (6), pp. 951-959. ISSN 0020-7136

Ali, SA, Ahmad, M ORCID: 0000-0002-6074-2001, Lynam, J, Mclean, CS, Entwisle, C, Loudon, P, Choolun, E, Mcardle, SE ORCID: 0000-0001-6929-9782, Li, G, Mian, S and Rees, RC, 2004. Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine, 22 (2728), pp. 3585-3594. ISSN 0264-410X

Ahmad, M ORCID: 0000-0002-6074-2001, Rees, RC and Ali, SA, 2004. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunology, Immunotherapy, 53 (10), pp. 844-854. ISSN 0340-7004

Ali, S, Ahmad, M ORCID: 0000-0002-6074-2001, Lynam, J, Rees, RC and Brown, N, 2004. Trafficking of tumor peptide-specific cytotoxic T lymphocytes into the tumor microcirculation. International Journal of Cancer, 110 (2), pp. 239-244. ISSN 0020-7136

Rees, RC, McArdle, SE ORCID: 0000-0001-6929-9782, Mian, S, Li, G, Ahmad, M ORCID: 0000-0002-6074-2001, Parkinson, R and Ali, SA, 2002. Disabled infectious single cycle-herpes simplex virus (DISC-HSV) as a vector for immunogene therapy of cancer. Current Opinion in Molecular Therapeutics, 4 (1), pp. 49-53. ISSN 1464-8431

Chapter in book

Assudani, DP, McArdle, SE ORCID: 0000-0001-6929-9782, Ahmad, M ORCID: 0000-0002-6074-2001, Li, G, Rees, RC and Ali, SA, 2008. Vaccination strategies for malignant diseases. In: Treatment of cancer. Hodder Arnold, p. 167.

Conference contribution

Assudani, DP, Ahmad, M ORCID: 0000-0002-6074-2001, Li, G, Rees, RC and Ali, SA, 2004. Immunotherapeutical potential of DISC-HSV and OX40L in cancer. In: Conference on Progress in Vaccination Against Cancer, Frendenstadt Lauterbad, Germany, 22-25 September 2004, Frendenstadt Lauterbad, Germany.

This list was generated on Tue Sep 26 18:09:49 2017 UTC.